Abbonarsi

Dynamic prognostication in non-ST–elevation acute coronary syndromes: insights from GUSTO-IIB and pursuit - 26/08/11

Doi : 10.1016/j.ahj.2003.05.004 
Wei-Ching Chang, PhD a, Eric Boersma, PhD c, Christopher B Granger, MD b, Robert A Harrington, MD b, Robert M Califf, MD b, Maarten L Simoons, MD c, Neal S Kleiman, MD d, Paul W Armstrong, MD a,

GUSTO-IIb and PURSUIT Investigators

a University of Alberta, Edmonton, Alberta, Canada 
b Duke Clinical Research Institute, Durham, NC, USA 
c Erasmus University, Rotterdam, The Netherlands 
d Baylor College of Medicine, Houston, Tex, USA 

*Reprint requests: Paul W. Armstrong, MD, Department of Medicine, 2-51 Medical Sciences Building, University of Alberta, Edmonton, Alberta T6G 2H7 Canada.

Abstract

Background

Risk assessment in patients with non-ST–elevation acute coronary syndromes (NSTE-ACS) traditionally focuses on and is limited to admission findings. The objective of the current study was to develop an approach to predicting outcome in NSTE-ACS that could account for the changing nature of risk.

Methods

In 7294 of 8010 patients with NSTE-ACS and complete electrocardiographic data in the GUSTO-IIb trial, we predicted the mortality probability at days 0–2, 0–30, 3–30, 5–30, and 7–30 using multiple logistic regression. Resulting risk estimates were incorporated into a composite, dynamic model to estimate the effects of changing probabilities over time. These models were validated against an independent sample of 9461 patients from the PURSUIT trial.

Results

As time passed after admission, the risk of 30-day death declined in stable patients. This risk, which was 3.72% at baseline, declined to 1.92% in 6-day survivors, and the risk reduction was greatest for those with the highest baseline risk. Importantly, however, the development of inhospital complications modified these trends. The use of dynamic models not only allowed us to estimate early (<48 h) mortality with a high degree of accuracy (C-index of 0.87), but also to continuously update the longer-term prognosis with increasing accuracy: the C-index increased from 0.75 for the day 0–30 model to 0.81 and 0.82 for the composite and day 7–30 models, respectively.

Conclusions

Dynamic risk assessment is feasible and reliable. This approach can improve risk assessment and provide valuable guidance for management of patients with NSTE-ACS.

Il testo completo di questo articolo è disponibile in PDF.

Mappa


 Guest Editor for this manuscript was Elliott M. Antman, MD, Brigham and Women's Hospital, Boston, Mass.


© 2004  Elsevier Inc. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 148 - N° 1

P. 62-71 - luglio 2004 Ritorno al numero
Articolo precedente Articolo precedente
  • Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials
  • The ONTARGET/TRANSCEND Investigators a * * * e1
| Articolo seguente Articolo seguente
  • Effects of a brief course of azithromycin on soluble cell adhesion molecules and markers of inflammation in survivors of an acute coronary syndrome: a double-blind, randomized, placebo-controlled study
  • Graham S Hillis, Claire V Pearson, Scott A Harding, Sheena Sutherland, Christopher A Ludlam, John C Marioni, Robin J Prescott, Keith A.A Fox, Andrew D Flapan

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.